多发性骨髓瘤市场规模、份额、成长分析、按药物类别、按治疗方法、按分销管道、按地区 - 行业预测，2024-2031

2022年全球多发性骨髓瘤市场规模将为219.8亿美元，从2023年的253亿美元成长到2031年的779.3亿美元，在预测期间（2024-2031年）预计将以复合年增长率增长。 2018 年为15.1%）。

由于人们对这种主要影响浆细胞的罕见血癌的认识不断提高和发病率不断上升，多发性骨髓瘤市场正在经历巨大的发展势头。随着新疗法的不断出现，竞争格局正在不断变化，市场参与企业的治疗专业知识也显着提高。根据Globocan 2020数据等报告，全球新诊断癌症患者人数为19,292,789人，癌症相关死亡人数约1,000万人。国际癌症研究机构 (IARC) 预测，到 2031 年，这一数字将上升至 2,750 万例新病例和 1,630 万人死亡，其中男性面临的风险是女性的 1.5 倍。主要风险因素包括吸烟和饮酒等生活方式的选择，以及男性肥胖率高。血癌盛行率的增加以及对医疗基础设施、研究和治疗方案的需求不断增加，推动了市场的成长。然而，全球多发性骨髓瘤市场的扩张在一定程度上受到开发中国家低治疗率的限制。目前，随着医疗保健产业致力于应对这项挑战，美国多发性骨髓瘤市场预计将在未来几年保持永续的年复合成长率（CAGR）。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 价值链分析
• 原料分析
• 价格分析
• 消费行为分析
• PESTEL分析

多发性骨髓瘤市场：依药物类别

• 市场概况
• 蛋白酶体抑制剂
• 免疫调节剂
• 单株抗体
• 类固醇

多发性骨髓瘤市场：依治疗方法

• 市场概况
• 免疫疗法
• 化疗
• 放射治疗
• 干细胞移植

多发性骨髓瘤市场：按分销管道

• 市场概况
• 医院
• 零售
• 网路药房

多发性骨髓瘤市场规模：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Bristol-Myers Squibb Company（US）
• Amgen Inc.（US）
• Johnson & Johnson（Janssen Pharmaceuticals）（US）
• Novartis AG（Switzerland）
• Sanofi（France）
• Takeda Pharmaceutical Company Limited（Japan）
• Pfizer Inc.（US）
• Celgene Corporation（Bristol-Myers Squibb Company）（US）
• AbbVie Inc.（US）
• Genentech, Inc.（F. Hoffmann-La Roche Ltd）（US）
• Karyopharm Therapeutics（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• ONO Pharmaceutical Co., Ltd.（Japan）
• Merck & Co., Inc.（US）
• Eli Lilly and Company（US）
• GlaxoSmithKline plc（UK）
• Bayer AG（Germany）
• Takeda Oncology（Millennium Pharmaceuticals）（Japan）
• Oncopeptides AB（Sweden）
• Bluebird Bio, Inc.（US）

Global Multiple Myeloma Market size was valued at USD 21.98 billion in 2022 and is poised to grow from USD 25.30 billion in 2023 to USD 77.93 billion by 2031, growing at a CAGR of 15.1% in the forecast period (2024-2031).

The multiple myeloma market is experiencing significant momentum driven by increasing awareness and rising incidence of this rare blood cancer, primarily affecting plasma cells. As new therapeutics continue to emerge, the competitive landscape is evolving, with a marked uptick in treatment expertise among leading market participants. Reports, such as the Globocan 2020 data, highlight a staggering 19,292,789 new cancer diagnoses worldwide, alongside nearly 10 million cancer-related fatalities. The International Agency for Research on Cancer (IARC) projects that these numbers will escalate to 27.5 million new cases and 16.3 million deaths by 2031, with men facing a 1.5-fold higher risk than women. Key risk factors include lifestyle choices like smoking, alcohol use, and higher obesity rates among men, while the disease predominantly affects older adults, particularly those aged 55 to 65. Contributing to market growth is the increasing incidence of hematological cancers and a growing demand for healthcare infrastructure, research, and treatment options. However, the proliferation of the global multiple myeloma market is somewhat curtailed by low treatment rates in developing nations. As it stands, the US multiple myeloma market is anticipated to maintain a sustainable compound annual growth rate (CAGR) in the forthcoming years, as the healthcare sector intensifies its focus on combating this challenging disease.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Myeloma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Myeloma Market Segmental Analysis

Global Multiple Myeloma Market is segmented on the drug class, therapy, distribution channel, and region. By drug class, market is segmented into Proteasome Inhibitors, Immunomodulatory Drugs, Monoclonal Antibodies, and Steroids. By therapy, market is segmented into immunotherapy, chemotherapy, radiation therapy, and stem cell transplant. By distribution channel, market is segmented into hospital, retail, and online pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Multiple Myeloma Market

The global multiple myeloma market is significantly driven by the increasing adoption of monoclonal antibodies, which are heralded for their high safety profile and targeted action against myeloma cells. Advances in nanomedicine and microRNA therapies, alongside the ongoing development of effective and safe treatments, are further propelling market growth. The integration of monoclonal antibodies, like Darzalex and Empliciti, with existing therapies enhances treatment efficacy, attracting clinician preference. Additionally, the rising incidence of hematological cancers, particularly multiple myeloma linked to specific genetic mutations, coupled with an aging population and rising healthcare costs, are amplifying the demand for innovative treatment solutions within this market.

Restraints in the Global Multiple Myeloma Market

The global multiple myeloma market is significantly restrained by low treatment rates in emerging nations, primarily driven by the high cost of treatments, which limits patient access. Furthermore, the scarcity of skilled healthcare professionals and inadequate healthcare infrastructure in these regions compound the issue, hindering effective diagnosis and treatment. The COVID-19 pandemic has exacerbated this situation, resulting in a notable decline in clinical visits and heightened reluctance among patients to seek medical care. Additionally, a pervasive lack of public awareness regarding multiple myeloma remains a critical barrier, ultimately impeding the market's growth potential throughout the forecast period.

Market Trends of the Global Multiple Myeloma Market

The global multiple myeloma market is experiencing a significant upward trend driven by increased research and development activities. This surge is fostering the introduction of novel therapies, evidenced by a rise in drug approvals and market entries, particularly in monoclonal antibodies like Darzalex and Empliciti. These advancements not only offer innovative treatment options, extending relapse intervals for patients, but also complement traditional therapies such as Revlimid and Velcade. Additionally, the emergence of second-generation proteasome inhibitors like Ninlaro and Kyprolis further diversifies treatment strategies, enhancing patient outcomes and solidifying the market's growth trajectory in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree Of Competition
• Top Investment Pockets
• Ecosystem Of the Market
• Value Chain Analysis
• Raw Material Analysis
• Pricing Analysis
• Consumer Behaviour Analysis
• PESTEL Analysis

Multiple Myeloma Market, By Drug Class

• Market Overview
• Proteasome Inhibitors
• Immunomodulatory Drugs
• Monoclonal Antibodies
• Steroids

Multiple Myeloma Market, By Therapy

• Market Overview
• Immunotherapy
• Chemotherapy
• Radiation Therapy
• Stem Cell Transplant

Multiple Myeloma Market, By Distribution Channel

• Market Overview
• Hospital
• Retail
• Online Pharmacies

Multiple Myeloma Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen Pharmaceuticals) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (Bristol-Myers Squibb Company) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (F. Hoffmann-La Roche Ltd) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ONO Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Oncology (Millennium Pharmaceuticals) (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncopeptides AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments